Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
Donald Trump's son-in-law has denied colluding with Moscow during a set of meetings with Russians ahead of the US presidential election.
Chocolate bars being shrunk in size by manufacturers have managed to bump up the total cost of producing the treats, new figures suggest.
Tackling the effects of the emerging drug has been described as one of the 'biggest challenges in policing' for 30 years.